SCHEMBL4240656

SCHEMBL4240656

CC(C)(C)[Si](C)(C)OCc1nc2cc(CO)ccc2[nH]1

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.36
RHEB Q15382 1/20 0.35
HSD17B10 Q99714 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
SMN1; SMN2 Q16637 6/20 0.34
NPC1 O15118 5/20 0.34
RAB9A P51151 5/20 0.34
TP53 P04637 3/20 0.34
POLB P06746 1/20 0.34
ALDH1A1 P00352 1/20 0.34
MAPK1 P28482 2/20 0.33
CBFB Q13951 2/20 0.33
MAPT P10636 2/20 0.33
MEN1 O00255 1/20 0.33
LMNA P02545 1/20 0.33
GAA P10253 1/20 0.33
HTT P42858 1/20 0.33
TSHR P16473 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4241835 0.88 RHEB (0.38) KMT2ARHEBHSD17B10TDP1NPC1
SCHEMBL4798414 0.80 NPSR1 (0.46) KMT2ATDP1SMN1; SMN2NPC1RAB9A
SCHEMBL4245924 0.79 SMN1; SMN2 (0.33) KMT2AHSD17B10SMN1; SMN2NPC1RAB9A
SCHEMBL4241794 0.78 SMN1; SMN2 (0.53) KMT2ARHEBSMN1; SMN2NPC1RAB9A
SCHEMBL5214411 0.78 NPC1 (0.55) KMT2ATDP1SMN1; SMN2NPC1RAB9A
SCHEMBL5029730 0.78 RAD52 (0.45) KMT2ARHEBTDP1SMN1; SMN2NPC1
SCHEMBL4337143 0.77 POLB (0.36) KMT2AHSD17B10TDP1SMN1; SMN2NPC1
SCHEMBL13508627 0.77 KMT2A (0.54) KMT2ATDP1SMN1; SMN2NPC1RAB9A
SCHEMBL11372794 0.76 DDAH1 (0.54) KMT2ARHEBHSD17B10TDP1SMN1; SMN2
SCHEMBL18663573 0.76 GAA (0.56) RHEBSMN1; SMN2RAB9AMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090048252-A1 THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION 2009-02-19 US disclosed
WO-2008096129-A1 NITROGEN CONTAINING HETROCYCLIC COMPOUNDS USEFUL AS BIFUNCTIONAL MODULATORS OF M3 RECEPTORS AND BETA- 2 RECEPTORS ARGENTA DISCOVERY LTD (GB) 2008-08-14 WO disclosed
US-20070249599-A1 Novel Chemical Compounds DUFFY KEVIN J 2007-10-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249599-A1 Novel Chemical Compounds HIPK3, HIPK1, HIPK4 KMT2A 2981/4885RHEB 899/4885HSD17B10 920/4885
US-20090048252-A1 THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS PIK3CA, BTK, PI4KA KMT2A 3096/4885RHEB 2747/4885HSD17B10 3245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.